NASDAQ
3.10USD
+0.10 (+3.51%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
19.6M
P/E
—
EPS
—
Beta
0.26
52W range
2.52-12.15
Day range
2.97–3.10
Open
3.10
Prev close
3.00
Volume
7.9K
Avg volume
24.9K
Dividend
0.00
IPO
2021-02-05
https://www.globenewswire.com/news-release/2026/07/12/3325846/0/en/Evaxion-presents-new-preclinical-data-for-cytomegalovirus-vaccine-program-EVX-V1.html · 7/12/2026+0.80
https://www.globenewswire.com/news-release/2026/06/12/3310899/0/en/Evaxion-receives-Prix-Galien-UK-Award-for-Best-digital-health-solution.html · 6/12/2026+0.90
https://www.globenewswire.com/news-release/2025/12/06/3201085/0/en/Evaxion-presents-new-data-for-EVX-04-a-cancer-vaccine-candidate-for-acute-myeloid-leukemia-at-ASH-Annual-Meeting.html · 12/6/2025+0.80
https://www.defenseworld.net/2025/11/29/brokerages-set-evaxion-a-s-sponsored-adr-nasdaqevax-price-target-at-12-33.html · 11/29/2025+0.60
https://www.globenewswire.com/news-release/2025/10/31/3178280/0/en/Evaxion-to-announce-business-update-and-third-quarter-2025-financial-results-on-November-6-2025.html · 10/31/2025+0.00
https://www.globenewswire.com/news-release/2025/10/27/3174481/0/en/Evaxion-appoints-Dr-Helen-Tayton-Martin-as-new-Chief-Executive-Officer.html · 10/27/2025+0.30
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
